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Abstract 
 
OBJECTIVE: With the increasing use of oral antineoplastic agents in cancer management,  patients and 
family members need to understand of how to obtain, safely handle, and store the medication, how and 
when the medications should be taken, and when to report toxic side effects to accomplish efficacious 
treatment.  
 
DATA SOURCES: Research based articles and conference presentations. 
 
CONCLUSION: Cancer centers to modify policies, protocols, or practices to assure safe and proper 
administration of oral antineoplastic agents.  
 
IMPLICATIONS FOR NURSING PRACTICE: Clinicians need to monitor and facilitate 
administration of oral antineoplastic agents, and ultimately improve clinical outcomes. 
 
 
 
KEY WORDS: Cancer, Oral Agents, Antineoplastic, Adherence, Scope of problems 
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Policy Implications 
Oncology remains one of the few medical specialties where most patients are treated with 
intravenous (IV) rather than oral medication. However, this is beginning to change with the rapid increase 
in the number of oral therapeutic agents. This new paradigm in care requires that oncologists, primary 
care physicians, nurses, and pharmacists collaborate on the delivery of care that is patient-centered and 
includes family caregivers. There are very specific sets of protections and safety policies and procedures 
for other routes of cancer therapy.1 However, cancer centers have failed to modify policies, protocols, or 
practices to integrate the use of oral therapeutics into practice. Use of oral agents requires an in-depth 
understanding of how to obtain the medications, how to safely handle and store the pills, of how and 
when the medications should be taken, and when to report toxic side effects. Patients and family members 
must have the knowledge and support to carry out administration of oral therapeutics in their home in 
order to accomplish efficacious treatment of their disease. The following sections discuss the cost of oral 
agents, how economics influence adherence, models of care, and how policies, procedures, and protocol 
may be modified to assure safe and efficacious use of oral therapeutics. 
The Cost of Oral Therapeutic Prescription Drugs 
Patients may be faced with financial challenges while taking oral therapeutics as the cost of oral 
chemotherapy can be expensive, ranging from $5,000 to $80,000. Further complicating the cost issue is 
the complexity of the reimbursement system for oral agents. Medicare Part D, Medicaid, and several 
private insurers cover some types of oral chemotherapy. However, the deductibles and co-pays are often 
burdensome to patients and their families. Consequently, this financial burden may interfere with access 
to the prescribed medication, impeding adherence.  
Specialty pharmacies. Historically, oncologist offices and retail pharmacies managed the 
distribution of chemotherapy.2 However, challenges with inventory, product knowledge, and management 
have led to more than three-fourths of healthcare providers using specialty pharmacies to dispense oral 
antineoplastics. The role of a specialty pharmacy is to 1) streamline the drug distribution, delivery, and 
management processes in ways that engage patients in their care; 2) help payers to understand the return 
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on investment in specialty drugs; and 3) assist manufacturers with inventory challenges and relationships 
with managed care organizations.2 Many challenges still exist in relation to managing financial concerns, 
effective distribution, data collection and outcome measurement to assure efficacious cancer treatment. 
Electronic systems for giving oncologists access to information on current prescription processing status, 
reimbursement information, and adherence for complex regimens are in development at most specialty 
pharmacies, but remain in their infancy. Specialty pharmacies are on the edge of becoming a major force 
in delivery of oral therapeutics. 
Access to payment for oral therapeutic prescription drugs. Many pharmaceutical companies 
sponsor drug assistance programs. However, busy clinicians do not have the time to understand the 
complexity of the drug assistance programs. In addition, many clinicians do not have access to the 
information to assist patients. Conversely, specialty pharmacies routinely assist patients and their 
families, as well as oncologist, with managing these financial challenges. Yet, little is known about how 
widely assistance information has been disseminated, patients’ responses to the assistance programs, or if 
assistance extends over the entire course of treatment. Access to oral agents may also be a problem for 
those who are low income, as most do not receive their care from comprehensive cancer centers and are 
rarely prescribed oral agents. 
Economic Factors Influencing Oral Therapeutics Adherence 
The correct use of medications is the most cost-effective way to manage disease and reduce 
healthcare cost.3 In general, economic factors are known to directly influence medication adherence. For 
example, difficulty with affording medications4 and the amount of the co-payment are directly associated 
with medication adherence.5 In some diseases, such as diabetes and hypercholesterolemia, a high level of 
medication adherence is directly associated with lower disease-related healthcare costs.6 However, a gap 
exists in the literature, with little known about the influence of economic factors, such as prescription 
benefits, co-payments or out-of-pocket cost, and adherence to oral antineoplastic agents. Understanding 
the cost of oral antineoplastics, how patients obtain these medication and payment assistance through 
specialty pharmacies, and how this affects healthcare costs is necessary for all clinicians. 
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It has already been established that oral agents have the potential to save medical resources and 
reduce costs. For example, in one of the phase III trials of capecitabine versus 5-FU/LV, patients 
receiving oral capecitabine made 72% fewer hospital visits for drug administration and spent 23% fewer 
days in the hospital for treatment related to adverse events, compared to those treated with IV 5-FU/LV.7 
The need for expensive drugs for managing adverse events was also substantially reduced with 
capecitabine.7 This may be true for all oral agents, creating significant savings in healthcare costs overall.  
There may be situations when patients are not adherent to oral therapeutics, but do not disclose 
that fact to the healthcare provider. As a result, therapy may be stepped up to a more intensive and 
expensive medication because it was determined that the patient was not responsive to the lower dosing. 
Or failed treatment can lead to drugs that are more expensive. In addition, diagnostic tests may be ordered 
to try to identify reasons for the patient’s poor response, adding further to the costs of therapy.8 Finally, 
when drugs are discontinued or changed, patients could find themselves with thousands of dollars of 
leftover medications. If non-adherence can be quickly identified, then it can be addressed and lower the 
economic burden of these expensive oral anti-cancer agents.  
Models of Care for Oral Therapeutic Usage 
Two models of care for promoting adherence to oral agents were found in the literature. One is a 
nursing-and pharmacy-led clinic and the other is an electronic monitoring system for adherence and 
symptom management. The following explains each. 
A nursing-and pharmacy-led clinic to promote adherence to capecitabine in metastatic colorectal 
cancer patients was tested as a model of care.9 An agreed upon treatment protocol that included criteria 
for referral to the clinics, authorization of the oral therapeutics, toxicity assessment, dose modification, 
and medication referrals, CT scans, and administration of adjunctive therapy. The main function of the 
clinic was to provide education and counseling for early detection and management of treatment side 
effects and for the clinicians to oversee management of any treatment related events. Emphasis was 
placed on the patient’s ability to recognize grade 2 toxicities during therapy so that subsequent 
interruption of therapy could reduce the occurrence of serious toxicities. Patients were provided diary 
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cards and a 24-hour telephone contact number for ongoing support. No costs of providing this clinic were 
reported. This model provides guidance for comprehensive cancer centers in how to restructure care for 
patients on oral agents. 
A recent pilot three-arm trial of 119 patients with solid tumors from four cancer centers used an 
educational approach to symptom management coupled with electronic reminders to take oral therapeutic 
agents.10 Participants first received a Symptom Management Toolkit® and then participated in an 
interview to determine the severity of 15 symptoms, satisfaction, and belief about oral agents. This was 
followed by weekly Automated Voice Response calls (and some had 1-2 nurse calls) for nonadherence or 
behavioral self-management, if symptoms were severe. The study demonstrated effective strategies for 
reducing symptom severity and sustaining adherence to oral chemotherapy.10 Further refinement of 
systems to manage oral agents need to occur prior to use in clinical practice. 
Policies, Procedures, and Processes of Care  
Administrators of cancer centers and clinicians can modify policies, procedures and processes of 
care integrating what is known about oral therapeutic agent use. This includes educating clinicians, 
patients and family members, monitoring adherence, addressing safe handling and administering of the 
pills, and addressing effective coordination of care. 
Education. Clinicians need to understand their role in providing education and counseling to 
patients on how to obtain the medications, how to safely handle and store the pills, and how and when the 
medications should be taken. They must also include instruction on when to report toxic side effects and 
how to oversee and manage any treatment related events. Emphasis should be placed on increasing the 
patient and caregiver’s ability to recognize grade 2 toxicities to allow for early interruption of therapy, 
which could reduce the occurrence of serious toxicities. Clinicians need to provide tips to promote 
adherence, such as pill boxes or setting alarms on cell phone. Patients and caregivers need to understand 
their role in obtaining the medications, safely handling and storing the pills, adherence to the regimen, 
and when and how to report toxic side effects. Monitoring adherence can be provided by clinicians, such 
as drug diary cards, which can then be brought to each subsequent office visit. 
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Coordination of care. An ongoing flow of communication between the patient, caregiver and 
provider is necessary. In addition, coordination with the specialty pharmacy helps assure the right drug, in 
the right amount, is provided at the right time, and allows for immediate attention to any changes in 
prescribed dosage, so that too much or too little will not be dispensed. Providing contact information for 
the pharmacist is helpful to the patient and caregiver, who may want to call the pharmacist with specific 
questions. A 24-hour telephone contact number for ongoing support with symptom management and 
toxicities is also helpful. This is a common practice in comprehensive cancer centers, however, this 
approach is not always discussed with patients and caregivers within the context of this type of treatment.  
Safety. There are multiple safety issues when taking oral therapeutics. First, over adherence 
(taking more than the prescribed dosage, either at the wrong time or day, or to make up for a missed dose) 
has been identified as a problem in numerous clinical trials.11 Clinicians need to discuss timing of 
medication administration, not making up missed doses (for agents that must be taken on a time 
schedule), and when to report over adherence to the clinician. Adverse events may occur, and patients and 
caregivers need to be prepared to recognize and then report the event to clinicians. Biohazardous residue 
may occur when handling the oral agent pills and patients and caregivers need to know when gloves are 
required for handling the pills, and how to store the pill containers in a safe environment where children 
do not have access to the pills. Finally, some pills may be leftover when the treatment is stopped, the 
disease progresses, or a new drug is started, and proper dispensing of these pills by taking them back to 
the pharmacy is often necessary. 
Payment and access to care. Developing a working relationship with a specialty pharmacy may 
be necessary for those clinicians who do not have the time or ability to assist patients with the complex 
reimbursement and access to care issues surrounding oral agents. Specialty pharmacies are becoming 
experts at solving payment problems by accessing pharmaceutical companies’ drug assistance programs. 
 In summary, establishing policies, procedures and processes of care that address each of these 
issues will support patients and their caregivers in the use of oral therapeutic agent use at home. These are 
the initial steps and will evolve as more is known about oral agents as therapeutics.  
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Conclusion 
The rise in use of targeted anti-cancer therapies, most of which are prescribed in oral form, raises 
a number of interesting policy issues. First, these agents are very expensive, their dosing is complex and 
the course of treatment is lengthy. Adherence is a crucial issue to the successful treatment and thus to the 
efficacy of these medications. All participants have a stake in examining how to modify the practice 
patterns in order to assure that these medications achieve their intended outcomes. Oncologists need to 
consider how to emphasize the importance of adherence and early reporting of side effects, and how to 
develop mechanisms for effective communication with their patients. Given the nature and complexity of 
oral agents, oncologists need to assume that mechanisms to prompt and manage adherence need to be put 
in place. The articles in this issue have reviewed alternatives for promoting and attaining sustained high 
rates of adherence. These efforts must be supported by payers. Oncologists need not bear the burden of 
adherence measurement and improvement alone. Payers can put into place standard, evidence-based 
quality indicators that provide reimbursement for high rates of patient adherence. With the advent of 
electronic medical records (EMRs) and electronic forms of monitoring, these evidence-based systems 
could be put into place quickly.  
Second, specialty pharmacies that package and deliver oral antineoplastic agents can participate 
in these emerging systems. Improved coordination of care between oncologists and the pharmacies that 
deliver medications to patients can lead to adjustment in deliveries reflecting changes in dosages or 
patients’ adherence rates. Furthermore, they can become an important vehicle for improving adherence, in 
assisting patients to obtain industry-supported financial assistance and to broker this information with 
oncologists.  
Third, patients and their family members need to understand clearly the importance of adherence 
to these agents. They need to understand that some side effects are indicators that the drug is working, but 
at the same time, strategies exist to minimize the side effects on their daily lives.  
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In this issue, a broad range of issues have been addressed regarding oral anti-cancer agents. This 
work begins to frame some examples of health care policies that might influence these new approaches to 
cancer therapy.  
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